Meningioma - Pipeline Review, H2 2017

  • ID: 4433852
  • Report
  • 229 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Co
  • Genentech Inc
  • GlaxoSmithKline Plc
  • MORE
Meningioma - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H2 2017, provides an overview of the Meningioma (Oncology) pipeline landscape.

A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Meningioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 8, 3, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Meningioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Meningioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Co
  • Genentech Inc
  • GlaxoSmithKline Plc
  • MORE
Introduction

Meningioma - Overview

Meningioma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Meningioma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Meningioma - Companies Involved in Therapeutics Development

Arno Therapeutics Inc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Eli Lilly and Co

Genentech Inc

GlaxoSmithKline Plc

Merck & Co Inc

Merck KGaA

Novartis AG

Ono Pharmaceutical Co Ltd

Pharma Mar SA

Progenics Pharmaceuticals Inc

Meningioma - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afatinib dimaleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-42 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Edotreotide Labeled Yttrium 90 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2256098 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HXR-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitrosylcobalamin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

R&D Progress

pasireotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

R&D Progress

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trabectedin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vismodegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vistusertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Meningioma - Dormant Projects

Meningioma - Discontinued Products

Meningioma - Product Development Milestones

Featured News & Press Releases

Sep 21, 2015: Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma

Jun 07, 2012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe

Feb 21, 2012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Meningioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Meningioma - Pipeline by Arno Therapeutics Inc, H2 2017

Meningioma - Pipeline by AstraZeneca Plc, H2 2017

Meningioma - Pipeline by Boehringer Ingelheim GmbH, H2 2017

Meningioma - Pipeline by Eli Lilly and Co, H2 2017

Meningioma - Pipeline by Genentech Inc, H2 2017

Meningioma - Pipeline by GlaxoSmithKline Plc, H2 2017

Meningioma - Pipeline by Merck & Co Inc, H2 2017

Meningioma - Pipeline by Merck KGaA, H2 2017

Meningioma - Pipeline by Novartis AG, H2 2017

Meningioma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Meningioma - Pipeline by Pharma Mar SA, H2 2017

Meningioma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017

Meningioma - Dormant Projects, H2 2017

Meningioma - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Meningioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Arno Therapeutics Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Co
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Merck KGaA
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Pharma Mar SA
  • Progenics Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll